The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism
Open accessAbstract
BACKGROUND: The length of time after an episode of venous thromboembolism during which the risk of newly diagnosed cancer is increased is not known, and whether vitamin K antagonists have an antineoplastic effect is controversial. METHODS: In a prospective, randomized study of the duration of oral anticoagulation (six weeks or six months) after a first episode of venous thromboembolism, patients were questioned annually about any newly diagnosed cancer. After a mean follow-up of 8.1 years, we used the Swedish Cancer Registry to identify all diagnoses of cancer and causes of death in the study population. The observed numbers of cases of cancer were compared with expected numbers based on national incidence rates, and the standardized incidence ratios were calculated. RESULTS: A first cancer was diagnosed in 111 of 854 patients (13.0 percent) during follow-up. The standardized incidence ratio for newly diagnosed cancer was 3.4 (95 percent confidence interval, 2.2 to 4.6) during the first year after the thromboembolic event and remained between 1.3 and 2.2 for the following five years. Cancer was diagnosed in 66 of 419 patients (15.8 percent) who were treated for six weeks with oral anticoagulants, as compared with 45 of 435 patients (10.3 percent) who were treated for six months (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.4). The difference was mainly due to the occurrence of new urogenital cancers, of which there were 28 cases in the six-week group (6.7 percent) and 12 cases in the six-month group (2.8 percent) (odds ratio, 2.5; 95 percent confidence interval, 1.3 to 5.0). The difference in the incidence of cancer between the treatment groups became evident only after two years of follow-up, and it remained significant after adjustment for sex, age, and whether the thromboembolism was idiopathic or nonidiopathic. Older age at the time of the venous thrombosis and an idiopathic thromboembolism were also independent risk factors for a diagnosis of cancer. No difference in the incidence of cancer-related deaths was detected. CONCLUSIONS: The risk of newly diagnosed cancer after a first episode of venous thromboembolism is elevated during at least the following two years. Subsequently, the risk seems to be lower among patients treated with oral anticoagulants for six months than among those treated for six weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Self-citationDeep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
Prandoni, P., Lensing, A. W. A., Büller, H. R., Cogo, A., Prins, M. H., Cattelan, A. M., Cuppini, S., Noventa, F., & ten Cate, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210153271604 · Cited by 680
The Risk of a Diagnosis of Cancer after Primary Deep Venous Thrombosis or Pulmonary Embolism
Sørensen, H. T., Mellemkjær, L., Steffensen, F. H., Olsen, J. H., & Nielsen, G. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804233381701 · Cited by 620
O'Neill, D. D., Westerman, D. P., & Sacco, W. (1966) · doi:10.21236/ad0635168 · Cited by 566
Venous thromboembolism and cancer
Baron, J. A., Gridley, G., Weiderpass, E., Nyren, O., & Linet, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10018-6 · Cited by 513
Zacharski, L. R. (1981) · JAMA · doi:10.1001/jama.245.8.831 · Cited by 206
Maurer, L. H., Herndon, J. E., Hollis, D. R., Aisner, J., Carey, R. W., Skarin, A. T., Perry, M. C., Eaton, W. L., Zacharski, L., Hammond, S., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3378 · Cited by 123
Taniguchi, T., Kakkar, A. K., Tuddenham, E. G. D., Williamson, R. C. N., & Lemoine, N. R. (1998) · PubMed · Cited by 112
Fernández-Patrón, C., Zhang, Y., Radomski, M. W., Hollenberg, M. D., & Davidge, S. T. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614389 · Cited by 30
Cited by
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Meyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., & Farge, D. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1729 · Cited by 796
Venous Thromboembolism and Cancer: Risks and Outcomes
Lee, A. Y. Y., & Levine, M. N. (2003) · Circulation · doi:10.1161/01.cir.0000078466.72504.ac · Cited by 721
Kakkar, A. K., Levine, M. N., Kadziola, Z., Lemoine, N. R., Low, V., Patel, H. K., Rustin, G., Thomas, M., Quigley, M., & Williamson, R. C. N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.002 · Cited by 650
Metadata
- Authors
- Schulman, S., & Lindmarker, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2000-06-29
- Volume
- 342
- Issue
- 26
- Pages
- 1953-1958
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2337548499
- Cited by
- 326
- References
- 9
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism. https://app.cochat.ai/papers/10.1056/nejm200006293422604
- The paper
- Schulman, S., & Lindmarker, P. (2000). Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism. New England Journal of Medicine. https://doi.org/10.1056/nejm200006293422604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.